Biohaven Pharmaceutical Holding Company Ltd

NYSE:BHVN   3:59:59 PM EDT
126.16
-1.20 (-0.94%)
4:00:00 PM EDT: $126.15 -0.01 (-0.01%)
Regulatory, Earnings Announcements

Sosei Says Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist With Biohaven

Published: 06/23/2021 07:13 GMT
Biohaven Pharmaceutical Holding Company Ltd (BHVN) - :sosei Heptares Initiates Phase 1 Trial With Novel Small-molecule Cgrp Antagonist Under Collaboration With Biohaven.
Sosei Heptares - Will Conduct Phase 1 Clinical Trial Itself, Receiving a Milestone Payment for Its Initiation.
Sosei - Initiates Phase 1 Trial With Novel Small-molecule Cgrp Antagonist Under Collaboration With Biohaven.
Sosei Heptares - First Clinical Trial With Lead Candidate Htl0022562 (bhv3100) to Be Conducted by Sosei Heptares.
Sosei Heptares- is Eligible for Development Costs for Conducting Trial; Biohaven Will Lead All Future Studies and Development Activities.
Sosei Heptares - Will Be Eligible for Further Milestone Payments and Royalties.
Sosei Heptares- Event Reported Today Has No Significant Impact on Consolidated Financial Results for Accounting Period Ending 31 December 2021.
Revenue is expected to be $54.73 Million
Adjusted EPS is expected to be -$3.15

Next Quarter Revenue Guidance is expected to be $98.14 Million
Next Quarter EPS Guidance is expected to be -$2.60

More details on our Analysts Page.